A major study published by researchers at Stanford Medicine reveals that estrogen-only menopausal hormone therapy is associated with a 35% lower risk of developing Alzheimer’s disease. Examining brain autopsies of older women, investigators found significantly fewer neuropathological signs of dementia among those who utilized estrogen-based regimens.
As a senior medical journalist, I’ve tracked the turbulent history of menopausal hormone therapy (MHT) for over two decades. Few medical interventions have experienced such a drastic swing in public perception. Following the publication of the Women’s Health Initiative (WHI) study in 2003, prescription rates plummeted from roughly 27% to below 5%. Patients and physicians grew deeply wary of systemic hormones, driven by warnings of elevated cardiovascular and oncological risks. But science is rarely static. The latest findings from Stanford, supported by data from the National Institutes of Health, demand a rigorous re-evaluation of how we manage neurological aging in post-menopausal patients.
In Plain English: The Clinical Takeaway
- Estrogen-Only Focus: The protective association observed in this study applies specifically to estrogen-only formulations, which are standard for women who have undergone a hysterectomy.
- Timing Matters: Historical and current clinical data suggest that initiating MHT during or soon after the onset of menopause yields the most favorable balance of health outcomes.
- Causality vs. Association: While the neuropathological evidence shows fewer Alzheimer’s plaques and tangles in brain autopsies, researchers emphasize this demonstrates a strong statistical association rather than absolute proof of direct causation.
Decoding the Stanford Brain Autopsy Data
Led by researchers at Stanford Medicine, the investigation analyzed brain autopsies to assess the presence of hallmark Alzheimer’s neuropathology—specifically amyloid-beta plaques and tau neurofibrillary tangles. The study adjusted for confounding factors, including education and race. The participant cohort skewed older, with an average age of 70, and many had previously undergone hysterectomies. Consequently, the analyzed population predominantly received estrogen-only regimens.
They may have focused on varying clinical outcomes, used divergent biomarkers or lumped together different MHT formulations, or studied different routes of administration or different durations of use. Some of those studies may not have adequately corrected for various genetic, cardiovascular or other risk factors.”
The biological mechanism of action centers on estrogen’s neuroprotective properties, including its ability to modulate cerebral blood flow, reduce neuroinflammation, and support synaptic plasticity. However, investigators caution that topical estrogen applications could not be evaluated as part of the study, and combined estrogen-plus-progestin therapies could not be evaluated with the same statistical certainty due to smaller sample sizes in those specific subgroups.
Historical Context and Regulatory Shifts
The shadow of the 2003 Women’s Health Initiative Memory Study has loomed large over women’s healthcare for over twenty years. That landmark analysis linked estrogen-plus-progestin combinations to increased risks of breast cancer and coronary heart disease. In 2025, the U.S. Food and Drug Administration (FDA) announced the removal of a black-box warning to this effect.
“For a long time, the going recommendation was ‘Don’t use MHT for memory decline,’” observed Dr. Bruno, co-investigator on the Stanford study. “This study flies in the face of that recommendation.” Despite this shifting regulatory and clinical stance, patient uptake remains suppressed. Estimates of women’s use of the therapy during their lifetimes were once close to 27%, but have plummeted to below 5%.
| Parameter | Estrogen-Only Regimen | Estrogen-Plus-Progestin Regimen |
|---|---|---|
| Target Patient Group | Women without a uterus (post-hysterectomy) | Women with an intact uterus |
| Alzheimer’s Autopsy Association | Associated with a 35% lower risk of neuropathological signs | Inconclusive due to limited sample size in autopsy cohort |
| Route of Administration | Oral formulations evaluated | Requires further large-scale longitudinal tracking |
Funding and Methodological Transparency
The underlying research was supported by grants from the National Institutes of Health (grants R01AG072470, R21AG073973, R21AG064263, R01AG073362, R61MH119289, R01MH123873 and 1K01AG083224).
“The recent medical literature suggests that MHT is more beneficial when initiated during or soon after menopause,” Hosseini explained. Because the Stanford study cohort averaged 70 years of age at evaluation, researchers believe the late initiation of therapy may have underestimated the benefit.
Contraindications & When to Consult a Doctor
Menopausal hormone therapy is not universally appropriate. Patients should schedule a consultation with a physician to determine if hormone therapy aligns with a patient’s overall health trajectory.
References:
- National Institutes of Health (NIH). Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology.
- Stanford Medicine. Study ties estrogen-based menopausal hormone therapy to lower Alzheimer’s risk. Stanford News.
- Scientific American. Estrogen-only hormone therapy could lower risk of Alzheimer’s.
